Literature DB >> 15542580

Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients.

Ewout J Houwerzijl1, Nel R Blom, Johannes J L van der Want, Henk Louwes, Mariet T Esselink, Jan W Smit, Edo Vellenga, Joost Th M de Wolf.   

Abstract

To investigate underlying mechanisms of thrombocytopenia in myelodysplastic syndrome (MDS), radiolabeled platelet studies were performed in 30 MDS patients with platelet counts less than 100 x 10(9)/L. Furthermore, plasma thrombopoietin and glycocalicin index (a parameter of platelet or megakaryocyte destruction) were determined. Mean platelet life (MPL), corrected for the degree of thrombocytopenia, was reduced in 15 of 30 patients (4.3 +/- 0.9 days [mean +/- SD] vs 6.0 +/- 1.3, P = .0003). Platelet production rate (PPR) was reduced in 25 of 30 patients (68 +/- 34 x 10(9)/d vs 220 +/- 65, P < .0001). Thrombopoietin levels were not significantly correlated with the PPR. However, the glycocalicin index was significantly higher compared with controls (15 +/- 16 vs 0.7 +/- 0.2, P = .001) and significantly correlated with the PPR (P = .02, r = -0.5), but not with the MPL (P = 1.8). Ultrastructural studies demonstrated necrosis-like programmed cell death (PCD) in mature and immature megakaryocytes (n = 9). Immunohistochemistry of the bone marrow biopsies demonstrated no positive staining of MDS megakaryocytes for activated caspase-3 (n = 24) or cathepsin D (n = 21), while activated caspase-8 was demonstrated in a subgroup of patients (5/21) in less than 10% of megakaryocytes. These results indicate that the main cause of thrombocytopenia in MDS is caspase-3-independent necrosis-like PCD resulting in a decreased PPR in conjunction with an increased glycocalicin index.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542580     DOI: 10.1182/blood-2004-06-2108

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes.

Authors:  Alex F Sandes; Mihoko Yamamoto; Sergio Matarraz; Maria de Lourdes L F Chauffaille; Sandra Quijano; Antonio López; Tsutomu Oguro; Eliza Y S Kimura; Alberto Orfao
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Comparative study of IgG binding to megakaryocytes in immune and myelodysplastic thrombocytopenic patients.

Authors:  Doaa I Elzaeem; Esmat A El Sharkawi; Eman M Zaki; Ayman G Ghobrial; Aliaa S Abd El-Fatah; Waleed M Abd El-Hamed
Journal:  Ann Hematol       Date:  2021-05-13       Impact factor: 3.673

3.  Calpain5 expression is decreased in endometriosis and regulated by HOXA10 in human endometrial cells.

Authors:  Ivan Penna; Hongling Du; Rui Ferriani; Hugh S Taylor
Journal:  Mol Hum Reprod       Date:  2008-09-30       Impact factor: 4.025

4.  Clinical efficacy of platelet transfusion therapy in patients with leukemia and analysis of risk factors for ineffective transfusion.

Authors:  Li Chen; Hao Zhou; Bo Guo; Zheng Guan
Journal:  Oncol Lett       Date:  2020-01-24       Impact factor: 2.967

Review 5.  Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.

Authors:  W Li; K Morrone; S Kambhampati; B Will; U Steidl; A Verma
Journal:  Leukemia       Date:  2015-10-26       Impact factor: 11.528

6.  Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis.

Authors:  Thomas Walenda; Thomas Stiehl; Hanna Braun; Julia Fröbel; Anthony D Ho; Thomas Schroeder; Tamme W Goecke; Björn Rath; Ulrich Germing; Anna Marciniak-Czochra; Wolfgang Wagner
Journal:  PLoS Comput Biol       Date:  2014-04-24       Impact factor: 4.475

7.  Elevated VMP1 expression in acute myeloid leukemia amplifies autophagy and is protective against venetoclax-induced apoptosis.

Authors:  Hendrik Folkerts; Albertus T Wierenga; Fiona A van den Heuvel; Roy R Woldhuis; Darlyne S Kluit; Jennifer Jaques; Jan Jacob Schuringa; Edo Vellenga
Journal:  Cell Death Dis       Date:  2019-05-29       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.